FDA Determines Regulatory Review Period for RYSTIGGO Patent Extension

Summary

The Food and Drug Administration (FDA) has published a notice determining the regulatory review period for RYSTIGGO, a human biological product, following a submission to the U.S. Patent and Trademark Office (USPTO) for patent extension.